These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 28353036)

  • 1. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A; Dalla Volta A
    Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].
    Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV
    Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer.
    Mitsiades N; Kaochar S
    Endocr Relat Cancer; 2021 Jul; 28(8):T19-T38. PubMed ID: 34128827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
    Shao C; Yu B; Liu Y
    Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
    Anantharaman A; Friedlander TW
    Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
    Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
    Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
    Chism DD; De Silva D; Whang YE
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1369-78. PubMed ID: 24927631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Imamura Y; Sadar MD
    Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
    Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
    Elife; 2023 Jan; 12():. PubMed ID: 36656639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y; Dehm SM
    Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.